Clinical Corner
Chomp Melanoma Screening
Chomp Melanoma: A Recap
Chomp Melanoma, a group composed of UF medical and undergraduate students, hosted a free skin cancer screening open to the public at UF HealthStreet on Southwest Archer Road. UF Health dermatologists as well as other local practitioners were on hand to perform skin cancer checks and to provide information about how people can perform self-checks at home.
The screening event was the first of the group’s efforts to increase awareness of the dangers of skin cancer through education and preventative measures.
The American Cancer Society reports that skin cancer is the most common type of cancer. Melanoma skin cancer, though it’s less common than other forms, is the most likely to grow and spread. The American Cancer Society estimates that more than 96,000 cases of melanoma will be diagnosed in the United States in 2019.
Clinical Trial Highlight: Refractory Cancers
This issue of the UFHCC Connection highlights clinical trials currently recruiting patients with refractory malignancies.
Questions about how to send a patient? Please contact the Clinical Trials Office at cancer-center@ufl.edu or 352.273.8675
This open-label dose escalation and dose expansion study tests a new liposomal Annamycin as a single agent for the treatment of adult patients with relapsed or refractory AML after standard induction therapy. Patients cannot have prior anthracycline cumulative dose >551 mg/m2 or the daunorubicin equivalent which is the recommended non-cardiotoxic level.
Principal Investigator: Jack Hsu, M.D., cell: 352.672.0704
This open-label, single arm study is investigating the use of niraparib (an oral PARPinhibitor) in patients with tumors known to have mutations in BAP1 and a variety of other DNA damage response pathway genes. The primary aim is to determine the objective response rate of patients with BAP1 and other DDR repair pathway deficiencies. Cohorts include the histologies above (regardless of mutation) as well as any tumor histology witha confirmed DDR repair pathway mutation.
Principal Investigator: Thomas George, M.D., cell: 352.339.6672
This open label study evaluates melflufen in combination with dexamethasone as treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or daratumumab. All patients will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle. Patients must have had a minimum of 2 prior lines of therapy (including an IMiD and a PI) and have disease refractory to pomalidomide and/or daratumumab.
Principal Investigator: John Hiemenz, M.D., cell: 352.360.9811
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (SWOG1609)
This Phase II umbrella trial is a sister study to the NCI-MATCH but specifically for rare histologies (nearly 50 such diagnoses) in patients who have been screened with next generation sequencing for MATCH, but for whom do not have a molecular treatment match. Treatment for all such patients includes nivolumab and ipilimumab. Newly available cohorts include several histologies in GYN, GU, GI, Sarcoma, and NETs.
Principal Investigator: Thomas George, M.D., cell: 352.339.6672